EFFICACY OF INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR STAGE 4 RETINOPATHY OF PREMATURITY

Purpose: To investigate the efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity. Methods: Retrospective case series study. The medical records of patients receiving intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity from January 2007 to May 2012 in Taipei Veterans General Hospital were reviewed. Results: A total of 13 eyes of 7 patients (3 boys and 4 girls) with Stage 4 retinopathy of prematurity were included. The mean gestational age and birth weight were 27.6 ± 2.6 weeks (range, 24.5–30.5 weeks) and 893.1 ± 293.2 g (range, 550–1422 g), respectively. The mean age at the time of injection was 38.2 ± 1.9 weeks (range, 36.0–41.5 weeks) postmenstrual age, and the mean follow-up period was 37.8 ± 19.5 months (range, 11.0–67.5 months). The active neovascularization regressed rapidly, and the anatomical outcomes were favorable in all patients. One eye developed recurrent retinal hemorrhage with localized retinal detachment 21 weeks after initial treatment, which resolved after a second injection. There were no ocular or systemic complications in these patients. Conclusion: Intravitreal injection of anti-vascular endothelial growth factor agents may be effective as monotherapy or as supplement to failed laser treatment for patients with Stage 4 retinopathy of prematurity without additional surgical intervention. Further randomized controlled trials are necessary to compare the clinical efficacy and safety with other conventional interventions.

[1]  B. Kirchhof,et al.  Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity , 2013, Acta ophthalmologica.

[2]  H. Quiroz-Mercado,et al.  Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity , 2012, British Journal of Ophthalmology.

[3]  S. J. Lichtenstein,et al.  Reactivation of retinopathy of prematurity after bevacizumab injection. , 2012, Archives of ophthalmology.

[4]  M. Shapiro,et al.  Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. , 2012, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[5]  F. Falcão-Reis,et al.  Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity , 2012, Case Reports in Ophthalmology.

[6]  A. Miki,et al.  INTRAOCULAR PRESSURE ELEVATION IS A DELAYED-ONSET COMPLICATION AFTER SUCCESSFUL VITRECTOMY FOR STAGES 4 AND 5 RETINOPATHY OF PREMATURITY , 2012, Retina.

[7]  S. Kusaka,et al.  Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. , 2012, American journal of ophthalmology.

[8]  S. Dimitrakos,et al.  Mediators involved in retinopathy of prematurity and emerging therapeutic targets. , 2011, Early human development.

[9]  L. Sirota,et al.  INTRAVITREAL BEVACIZUMAB AS SUPPLEMENTAL TREATMENT OR MONOTHERAPY FOR SEVERE RETINOPATHY OF PREMATURITY , 2011, Retina.

[10]  C. Meyer,et al.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab , 2011, Eye.

[11]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[12]  M. Morales-Cruz,et al.  Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. , 2011, Cirugia y cirujanos.

[13]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[14]  A. Kychenthal,et al.  VITRECTOMY AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL DETACHMENT IN RETINOPATHY OF PREMATURITY , 2010, Retina.

[15]  T. Fujikado,et al.  Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. , 2009, Ophthalmology.

[16]  T. Yokoi,et al.  Evaluation of scleral buckling for stage 4A retinopathy of prematurity by fluorescein angiography. , 2009, American journal of ophthalmology.

[17]  T. Fujikado,et al.  Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. , 2009, Ophthalmology.

[18]  Darius M Moshfeghi,et al.  Incidence of retinopathy of prematurity in the United States: 1997 through 2005. , 2009, American journal of ophthalmology.

[19]  T. Fujikado,et al.  Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study , 2008, British Journal of Ophthalmology.

[20]  A. Capone,et al.  THREE-YEAR ANATOMIC AND VISUAL OUTCOMES AFTER VITRECTOMY FOR STAGE 4B RETINOPATHY OF PREMATURITY , 2008, Retina.

[21]  A. Negi,et al.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  A. Kychenthal,et al.  25-GAUGE LENS-SPARING VITRECTOMY FOR STAGE 4A RETINOPATHY OF PREMATURITY , 2008, Retina.

[23]  M. Martinez-Castellanos,et al.  ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY , 2008, Retina.

[24]  R. Avery,et al.  Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy , 2007, British Journal of Ophthalmology.

[25]  William V Good,et al.  The Incidence and Course of Retinopathy of Prematurity: Findings From the Early Treatment for Retinopathy of Prematurity Study , 2005, Pediatrics.

[26]  Anna L. Ells,et al.  The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.

[27]  R. Lakhanpal,et al.  Lens clarity after 3-port lens-sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity. , 2005, Archives of ophthalmology.

[28]  R. Lakhanpal,et al.  Anatomic success rate after 3-port lens-sparing vitrectomy in stage 4A or 4B retinopathy of prematurity. , 2005, Ophthalmology.

[29]  M. Trese,et al.  Refractive changes associated with scleral buckling and division in retinopathy of prematurity. , 1998, Archives of ophthalmology.

[30]  M. Repka,et al.  Scleral buckling surgery for active stage 4A retinopathy of prematurity. , 1998, Ophthalmology.

[31]  A. Fielder,et al.  EPIDEMIOLOGY OF RETINOPATHY OF PREMATURITY , 1988, The Lancet.

[32]  Chung-May Yang,et al.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. , 2011, Ophthalmology.

[33]  L. C. Zepeda-Romero,et al.  Paradoxical vascular–fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity , 2010, Eye.

[34]  A. Fielder,et al.  Natural history of retinopathy of prematurity: A prospective study , 1992, Eye.